Advertisement

Clinical Rheumatology

, Volume 38, Issue 2, pp 545–553 | Cite as

Study of clinical utility of antibodies to phosphatidylserine/prothrombin complex in Asian-Indian patients with suspected APS

  • Arvind Ganapati
  • Ruchika Goel
  • Jayakanthan Kabeerdoss
  • Mahasampath Gowri
  • John Mathew
  • Debashish DandaEmail author
Original Article
  • 37 Downloads

Abstract

Antiphospholipid syndrome (APS) is the most common acquired pro-thrombotic disorder, also associated with obstetric complications. Phosphatidylserine/Prothrombin complex antibody (aPSPT) though associated with various APS manifestations, is not included in the revised Sapporo Criteria. To study the prevalence of aPSPT in Asian-Indian patients with suspected APS and compare its performance with the criteria anti-phospholipid antibodies (APLs). Electronic charts of 372 individuals whose sera was tested for aPSPT in suspected APS between June 2014 and May 2016 were retrieved and analyzed. aPSPT was assayed by ELISA. aPSPT tested individuals were categorized into cases—seropositive and seronegative APS (SNAPS) and controls. aPSPT was positive in 24/58 (41.3%) cases and 17/314 (5.4%) controls (p < 0.001). aPSPT positivity was seen in 44.5%, 38.7%, and 58.4% in primary, secondary and SNAPS patients respectively. aPSPT had the best performance among all APLs, in obstetric APS with 31% sensitivity, 97.7% specificity, and an odds ratio of 18.8. It showed 41.4% sensitivity, 94.6% specificity for the classification/diagnosis of primary APS and 38.7% sensitivity, 91.5% specificity for secondary APS. Addition of aPSPT to current APS criteria to SNAPS patients led to reclassification of additional 12.1% patients as APS overall and 42.8% in obstetric APS category. In Asian-Indian patients with suspected APS, aPSPT outperformed all classical APLs in diagnosis/classification of obstetric APS and both isotypes of beta 2-glycoprotein-I antibodies in diagnosis/classification of APS. aPSPT could reclassify additional 12.1 and 42.8% patients as APS overall and obstetric APS respectively, over and above the cases satisfying revised Sapporo criteria.

Keywords

Antiphosphatidylserine prothrombin complex antibody APS aPSPT Obstetric APS Seronegative APS 

Notes

Acknowledgements

The authors would like to thank the institutional review board of Christian Medical College, Vellore, India for approval of the study.

Compliance with ethical standards

The study was approved by the institutional review board (IRB) and performed in accordance with the guidelines prescribed by the ethics committee of Christian Medical College, Vellore with approval no: IRB no. 11001(retro) dated 22/11/2017. A special waiver of consent was duly obtained from the IRB in view of this study being of a retrospective design.

Disclosures

None.

Supplementary material

10067_2018_4301_MOESM1_ESM.docx (86 kb)
Supplementary Table 1 (DOCX 86 kb)

References

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefGoogle Scholar
  2. 2.
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42(7):1309–1311CrossRefGoogle Scholar
  3. 3.
    Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019–1027CrossRefGoogle Scholar
  4. 4.
    Sater MS, Finan RR, Abu-Hijleh FM, Abu-Hijleh TM, Almawi WY (2012) Anti-phosphatidylserine, anti-cardiolipin, anti-β2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks. Eur J Obstet Gynecol Reprod Biol 163(2):170–174CrossRefGoogle Scholar
  5. 5.
    Tincani A, Morozzi G, Afeltra A, Alessandri C, Allegri F, Bistoni O, Bizzaro N, Caccavo D, Galeazzi M, Gerli R, Giovannelli L, Longobardo G, Lotzniker M, Malacarne F, Migliorini P, Parodi A, Pregnolato F, Radice A, Riccieri V, Ruffelli M, Sinico RA, Tozzoli R, Villalta D, Marcolongo R, Meroni P, Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) (2007) Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol 25(2):268–274Google Scholar
  6. 6.
    Bardin N, Alessi MC, Dignat-George F, Vague IJ, Sampol J, Harlé JR, Sanmarco M (2007) Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology 212(7):557–565CrossRefGoogle Scholar
  7. 7.
    Sugiura-Ogasawara M, Atsumi T, Ozaki Y, Koike T, Suzumori K (2004) Phosphatidylserine-dependent antiprothrombin antibodies are not useful markers for high-risk women with recurrent miscarriages. Fertil Steril 82(5):1440–1442CrossRefGoogle Scholar
  8. 8.
    Bertolaccini ML, Atsumi T, Koike T, Hughes GRV, Khamashta MA (2005) Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 93(2):289–297CrossRefGoogle Scholar
  9. 9.
    Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, Koike T (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43(9):1982–1993CrossRefGoogle Scholar
  10. 10.
    Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y (2006) The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 91(5):699–702Google Scholar
  11. 11.
    Matsuda J, Sanaka T, Nishizawa A, Gotoh M, Gohchi K (2002) Two antiprothrombin antibodies against prothrombin and prothrombin-phosphatidyl serine show partial but not total identity. Blood Coagul Fibrinolysis 13(8):697–702CrossRefGoogle Scholar
  12. 12.
    Amengual O, Atsumi T, Koike T (2003) Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 48(4):886–895CrossRefGoogle Scholar
  13. 13.
    Yamada M, Kawakami T, Takashima K, Nishioka Y, Nishibata Y, Masuda S et al (2017) Establishment of a rat model of thrombosis induced by intravenous injection of anti-phosphatidylserine-prothrombin complex antibody. Rheumatol (Oxford) 56(6):1013–1018Google Scholar
  14. 14.
    Hughes GRV, Khamashta MA (2003) Seronegative antiphospholipid syndrome. Ann Rheum Dis 62(12):1127CrossRefGoogle Scholar
  15. 15.
    Shi H, Zheng H, Yin Y-F, Hu Q-Y, Teng J-L, Sun Y, Liu HL, Cheng XB, Ye JN, Su YT, Wu XY, Zhou JF, Norman GL, Gong HY, Shi XM, Peng YB, Wang XF, Yang CD (2018) Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med 56(4):614–624CrossRefGoogle Scholar
  16. 16.
    Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the ISTH. Thromb Haemost 74(4):1185–1190CrossRefGoogle Scholar
  17. 17.
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7(10):1737–1740CrossRefGoogle Scholar
  18. 18.
    Kopytek M, Natorska J, Undas A (2018) Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. Lupus 27(5):812–819CrossRefGoogle Scholar
  19. 19.
    Vlagea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, Pascual-Salcedo D (2013) Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 19(3):289–296CrossRefGoogle Scholar
  20. 20.
    Canti V, Del Rosso S, Tonello M, Lucianò R, Hoxha A, Coletto LA et al (2018) Antiphosphatidylserine/prothrombin antibodies in antiphospholipid syndrome with intrauterine growth restriction and preeclampsia. J Rheumatol 45(9):1263–1272CrossRefGoogle Scholar
  21. 21.
    Nakamura H, Oku K, Amengual O, Ohmura K, Fujieda Y, Kato M, Bohgaki T, Yasuda S, Atsumi T (2018) First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: a combination of anti-β2 -glycoprotein I domain I and anti-phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res 70(4):627–634CrossRefGoogle Scholar
  22. 22.
    Zhu L, Li C, Liu N, Yang X, Jia RL, Mu R, Su Y, Li ZG (2017) Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients. Clin Rheumatol 36(2):401–406CrossRefGoogle Scholar
  23. 23.
    Heikal NM, Jaskowski TD, Malmberg E, Lakos G, Branch DW, Tebo AE (2015) Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. Clin Exp Immunol 180(2):218–226CrossRefGoogle Scholar
  24. 24.
    Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, Chantarangkul V, Bertero T, de Micheli V, Borghi MO, Meroni PL (2013) Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res 56(2–3):432–438CrossRefGoogle Scholar
  25. 25.
    Žigon P, Perdan Pirkmajer K, Tomšič M, Kveder T, Božič B, Sodin Šemrl S, Čučnik S, Ambrožič A (2015) Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes. J Immunol Res 2015:1–8Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Department of Clinical Immunology and RheumatologyChristian Medical College VelloreIndia
  2. 2.Department of BiostatisticsChristian Medical College VelloreIndia

Personalised recommendations